Priority 2 from the Autosomal Dominant Polycystic Kidney Disease Project

UNCERTAINTY: Which people with ADPKD would benefit from early treatment and how can doctors identify them?  (Priority 2)
Overall ranking 2
JLA question ID 0103/2
Explanatory note Not available for this PSP
Evidence

No evidence identified

Health Research Classification System category Renal and urogenital
Extra information provided by this project
Original uncertainty examples Development of criteria for individualisation of treatments for polycystic liver disease, in people with ADPKD, and evaluation of treatment outcomes. ~ In people with ADPKD which interventions are effective and safe for preventing progression of the disease, considering outcomes such as progression to ESKD, need for transplantation, mortality, hospital admissions, major morbidities and quality of life? ~ Implementation of methods to routinely assess prognosis in patients with ADPKD to inform clinical decision-making, research and innovation. ~ What is the role of modifier genes in predicting disease progression in people with ADPKD? 
Submitted by 3 x research recommendations and Kidney Disease Improving Global Outcomes (KDIGO) 
Project information
Project unique ID 0103
Project name Autosomal Dominant Polycystic Kidney Disease
Total number of uncertainties identified by this project.

35 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)

Date of priority setting workshop 15 December 2020